Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Appoints Scott Morrison to Board of Directors
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the appointment of Scott Morrison, who brings 35 years of financial experience helping life sciences companies excel from start-up, through initial product launch, to global expansion.
“Scott Morrison is a well-respected industry leader who has successfully guided numerous life science companies through the opportunities and challenges faced at every stage of development,” said Ted W. Love, M.D., chief executive officer of GBT. “We look forward to being able to benefit from his strong financial acumen and general knowledge of the biotech community as we continue to move our proprietary product portfolio forward.”
Mr. Morrison served as Ernst & Young’s U.S. Life Sciences Leader since 2002 (retired December 2015). He has worked on hundreds of public and private financings, including more than 40 IPOs and 100 follow-on offerings and is considered a recognized expert in the M&A arena. Mr. Morrison served on the boards of the Bay Area Bioscience Center (BayBio), the Biotechnology Institute, the Biotechnology Industry Organization (BIO) ECS Board and the California Life Sciences Foundation. He has also co-authored several annual reports on the industry. He graduated from the University of California, Berkeley and is a Certified Public Accountant (inactive).
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS), as well as hereditary angioedema (HAE).
